David A. Siegel Brainstorm Cell Therapeutics Inc. Transaction History

Two Sigma Advisers, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$2.71 - $3.6 $29,810 - $39,600	-11,000 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$2.92 - $4.19 $1,752 - $2,514	-600 Reduced 5.17%	11,000 $37,000
Q4 2021 Feb 14, 2022	BUY	$2.81 - $4.23 $2,529 - $3,807	900 Added 8.41%	11,600 $46,000
Q3 2021 Nov 15, 2021	SELL	$3.14 - $4.09 $28,260 - $36,810	-9,000 Reduced 45.69%	10,700 $35,000
Q2 2021 Aug 16, 2021	SELL	$3.01 - $4.01 $303,107 - $403,807	-100,700 Reduced 83.64%	19,700 $75,000

Q1 2021 May 17, 2021	BUY	$3.46 - $7.88 $416,584 - $948,752	120,400 New	120,400 $461,000

4.09M

63.2K

800

Ticker BCLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,486,200
Market Cap $12.8M
Description
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem ...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.